Skip to main content

Table 1 Baseline characteristics at CRRT initiation in the original and the matched cohort

From: The benefit of specialized team approaches in patients with acute kidney injury undergoing continuous renal replacement therapy: propensity score matched analysis

Variables Original cohort P-value Matched cohort P-value
Before SCT (n = 223) After SCT (n = 311) Before SCT (n = 167) After SCT (n = 167)
Age, years 62.8 ± 14.0 61.6 ± 15.1 0.350 63.2 ± 13.6 63.1 ± 15.1 0.961
Male, n (%) 131 (58.7%) 212 (68.2%) 0.028 99 (59.3%) 99 (59.3%) >0.999
Mean arterial pressure, mmHg 80.7 ± 17.3 78.7 ± 16.0 0.168 80.7 ± 17.5 79.9 ± 15.2 0.881
APACHE II score 28.4 ± 8.6 26.1 ± 7.0 0.029 27.6 ± 8.1 27.4 ± 6.9 0.783
Sequential organ failure assessment score 14.2 ± 3.9 11.9 ± 3.4 0.031 12.1 ± 2.8 12.1 ± 3.3 0.958
Age-adjusted Charlson comorbidity index 6.1 ± 3.5 5.7 ± 3.0 0.365 5.9 ± 3.1 5.7 ± 2.8 0.886
RIFLE, n (%)    0.647   0.901
  Risk 96 (43.1%) 140 (45.0%)   75 (44.9%) 75 (44.9%)  
  Injury 79 (35.4%) 108 (34.7%)   56 (33.5%) 59 (35.3%)  
  Failure 48 (21.5%) 63 (20.3%)   36 (21.6%) 33 (19.8%)  
Contributing factors, n (%)    0.681   0.849
  Sepsis 112 (50.2%) 158 (50.8%)   87 (52.1%) 88 (52.7%)  
  Hemodynamic instability without sepsis 84 (37.7%) 106 (34.1%)   55 (32.9%) 51 (30.5%)  
  Major surgery 27 (12.1%) 47 (15.1%)   25 (15.0%) 28 (16.8%)  
Use of anticoagulation, n (%) 179 (80.3%) 235 (75.6%) 0.209 129 (77.2%) 128 (76.6%) 0.891
Diuretics use, n (%) 178 (79.8%) 246 (79.1%) 0.831 129 (77.2%) 128 (76.6%) 0.787
Biochemical data    
  Hemoglobin, g/L 92 ± 18 92 ± 18 0.987 92 ± 18 92 ± 19 0.837
  Whole blood cells, 103/mm3 15.6 ± 12.2 14.1 ± 10.5 0.174 15.2 ± 12.0 14.5 ± 11.0 0.577
  Blood urea nitrogen, mmol/L 20.2 ± 9.5 19.0 ± 10.4 0.166 20.7 ± 9.8 18.7 ± 10.0 0.066
  Creatinine, umol/L 300.6 ± 167.9 309.4 ± 203.3 0.681 318.2 ± 176.8 300.6 ± 185.6 0.393
  Total cholesterol, mmol/L 95.2 ± 45.5 92.3 ± 43.4 0.495 95.5 ± 45.9 91.6 ± 41.3 0.411
  Albumin, g/L 26 ± 6 27 ± 6 0.209 26 ± 6 28 ± 6 0.106
  C-reactive protein, mg/L 14.3 ± 12.0 12.4 ± 12.7 0.106 14.4 ± 11.9 12.8 ± 11.2 0.300
  Arterial pH 7.4 ± 0.1 7.3 ± 0.4 0.174 7.3 ± 0.1 7.3 ± 0.5 0.080
  Total bilirubin, umol/L 68.4 ± 123.1 63.3 ± 109.4 0.602 66.7 ± 119.7 63.3 ± 100.9 0.814
  HCO3 , mmol/L 19.9 ± 4.9 19.2 ± 5.5 0.157 20.0 ± 4.8 19.1 ± 5.7 0.125
  1. Data are presented as n (%) or mean ± SD. CRRT, continuous renal replacement therapy; SCT, specialized CRRT team; APACHE II, acute physiology and chronic health evaluation II; RIFLE, risk, injury, failure, loss, and end kidney disease.